These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3369134)

  • 1. Progressive loss of fibronectin-mediated opsonic activity in plasma cryoprecipitate with storage. Role of fibronectin fragmentation.
    Blumenstock FA; Valeri CR; Saba TM; Cho E; Melaragno A; Gray A; Lewis M
    Vox Sang; 1988; 54(3):129-37. PubMed ID: 3369134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of fibronectin and opsonic deficiency in patients. A controlled study.
    Saba TM; Blumenstock FA; Shah DM; Kaplan JE; Cho E; Scovill W; Stratton H; Newell J; Gottlieb M; Sedransk N
    Ann Surg; 1984 Jan; 199(1):87-96. PubMed ID: 6362585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma fibronectin (opsonic glycoprotein): its synthesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma as related to reticuloendothelial function.
    Saba TM; Jaffe E
    Am J Med; 1980 Apr; 68(4):577-94. PubMed ID: 6768291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of opsonic deficiency in surgical, trauma, and burn patients by infusion of purified human plasma fibronectin. Correlation with experimental observations.
    Saba TM; Blumenstock FA; Shah DM; Landaburu RH; Hrinda ME; Deno DC; Holman JM; Cho E; Dayton C; Cardarelli PM
    Am J Med; 1986 Feb; 80(2):229-40. PubMed ID: 3946437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new assay for fibronectin opsonic activity and its application to plasma and plasma fractions.
    Chang MD; Chin S; Horowitz B
    Vox Sang; 1985; 48(4):217-28. PubMed ID: 3984307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung vascular permeability after reversal of fibronectin deficiency in septic sheep. Correlation with patient studies.
    Saba TM; Niehaus GD; Scovill WA; Blumenstock FA; Newell JC; Holman J; Powers SR
    Ann Surg; 1983 Nov; 198(5):654-62. PubMed ID: 6416192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a rapid immunoturbidimetric assay for opsonic fibronectin in surgical and trauma patients.
    Saba TM; Albert WH; Blumenstock FA; Evanega G; Staehler F; Cho E
    J Lab Clin Med; 1981 Oct; 98(4):482-91. PubMed ID: 7288265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of factor VIII-rich cryoprecipitate and the plasma fibronectin-rich, heparin-precipitable fraction prepared from single-donor plasma units.
    Menitove JE; Amrani DL; Meh D; Frenzke M; Mosesson MW
    Transfusion; 1987; 27(6):491-5. PubMed ID: 3500532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibronectin in liquid and frozen stored blood components.
    Snyder EL; Ferri PM; Mosher DF
    Transfusion; 1984; 24(1):53-6. PubMed ID: 6420955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification of the opsonic activity of fibronectin by a plasma factor lacking gelatin affinity.
    Blumenstock FA; Saba TM; Cardarelli PM; Cho E
    J Reticuloendothel Soc; 1983 Jan; 33(1):21-33. PubMed ID: 6834358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of gelatin on bioassayable and immunoreactive opsonic fibronectin.
    Niehaus GD; Dillon BC; Schumacker PT; Saba TM
    Proc Soc Exp Biol Med; 1981 Oct; 168(1):15-23. PubMed ID: 7323064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular hemodynamics after opsonic alpha-2-surface binding glycoprotein therapy in injured patients.
    Scovill WA; Annest SJ; Saba TM; Blumenstock FA; Newell JC; Stratton HH; Powers SR
    Surgery; 1979 Aug; 86(2):284-93. PubMed ID: 88771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of antihemophilic factor and fibronectin from human plasma cryoprecipitate.
    Horowitz B; Lippin A; Chang MY; Shulman RW; Vandersande J; Stryker MH; Woods KR
    Transfusion; 1984; 24(4):357-62. PubMed ID: 6431661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational changes and loss of opsonic function in frozen or heat-treated plasma fibronectin.
    Boughton BJ; Simpson A; Wharton C
    Vox Sang; 1984; 46(5):254-9. PubMed ID: 6730422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actin-induced reticuloendothelial phagocytic depression as mediated by its interaction with fibronectin.
    Dillon BC; Estes JE; Saba TM; Blumenstock FA; Cho E; Lee SK; Lewis EP
    Exp Mol Pathol; 1983 Apr; 38(2):208-23. PubMed ID: 6832344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma fibronectin concentrations in blood products.
    Perttilä J; Salo M; Peltola O
    Intensive Care Med; 1990; 16(1):41-3. PubMed ID: 2107234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dynamics of the plasma fibronectin level in patients with food poisoning].
    Pak SG; Bogin IB; Kakhnovskaia NL; Sokurenko EV; Berchenko VV
    Ter Arkh; 1988; 60(11):71-5. PubMed ID: 3238583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opsonic alpha2 surface binding glycoprotein therapy during sepsis.
    Scovill WA; Saba TM; Blumenstock FA; Bernard H; Powers SR
    Ann Surg; 1978 Oct; 188(4):521-9. PubMed ID: 697436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood-borne fragments of fibronectin after thermal injury.
    La Celle P; Blumenstock FA; Saba TM
    Blood; 1991 May; 77(9):2037-41. PubMed ID: 2018840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating immunoreactive and bioassayable opsonic plasma fibronectin during experimental tumour growth.
    Saba TM; Gregory TJ; Blumenstock FA
    Br J Cancer; 1980 Jun; 41(6):956-65. PubMed ID: 7426320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.